AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.

Astrazeneca (AZN) closed the most recent trading day at $94.23, moving +1.38% from the previous trading session. The stock ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.

AstraZeneca PLC (NASDAQ:AZN) is one of the best healthcare stocks to buy for 2026. On January 29, AstraZeneca announced a $15 ...

AstraZeneca (NASDAQ:AZN) has announced it will shift its US listing from Nasdaq to the New York Stock Exchange, delisting its ...

Under the deal, the FTSE 100 group will have the exclusive global rights, outside China, to CSPC's once-a-month jab that is ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.

By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...

CSPC said earlier Friday that it entered an obesity drug agreement with AstraZeneca that would give the U.K.-based pharmaceutical company rights outside China to its clinical-ready long-acting obesity ...

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...

AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s ...